This Article Full Text Full Text (PDF) Other Versions of this Article: JVI.00319-08v1 82/13/6349    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by He, Y. Articles by Dai, Q. PubMed PubMed Citation Articles by He, Y. Articles by Dai, Q.

 Previous Article  |  Next Article 

Journal of Virology, July 2008, p. 6349-6358, Vol. 82, No. 13
0022-538X/08/$08.00+0     doi:10.1128/JVI.00319-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Identification of a Critical Motif for the Human Immunodeficiency Virus Type 1 (HIV-1) gp41 Core Structure: Implications for Designing Novel Anti-HIV Fusion Inhibitors

AIDS Research Center, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China,¹ Institute of Biotechnology, Chinese Academy of Military Medical Sciences, Beijing 100071, China,² Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York 10021³

Received 13 February 2008/ Accepted 7 April 2008

Human immunodeficiency virus type 1 (HIV-1) entry into the host cell involves a cascade of events and currently represents one of most attractive targets in the search for new antiviral drugs. The fusion-active gp41 core structure is a stable six-helix bundle (6-HB) folded by its trimeric N-terminal heptad repeat (NHR) and C-terminal heptad repeat (CHR). Peptides derived from the CHR region of HIV-1 gp41 are potent fusion inhibitors that target the NHR to block viral and cellular membrane fusion in a dominant negative fashion. However, all CHR peptides reported to date are derived primarily from residues 628 to 673 of gp41; little attention has been paid to the upstream sequence of the pocket binding domain (PBD) in the CHR. Here, we have identified a motif (⁶²¹QIWNNMT⁶²⁷) located at the upstream region of the gp41 CHR, immediately adjacent to the PBD (⁶²⁸WMEWEREI⁶³⁵). Biophysical characterization demonstrated that this motif is critical for the stabilization of the gp41 6-HB core. The peptide CP621-652, containing the ⁶²¹QIWNNMT⁶²⁷ motif, was able to interact with T21, a counterpart peptide derived from the NHR, to form a typical 6-HB structure with a high thermostability (thermal unfolding transition [T_m] value of 82°C). In contrast, the 6-HB formed by the peptides N36 and C34, which has been considered to be a core structure of the fusion-active gp41, had a T_m of 64°C. Different from T-20 (brand name Fuseon), which is the first and only HIV-1 fusion inhibitor approved for clinical use, CP621-652 could efficiently block 6-HB formation in a dose-dependent manner. Significantly, CP621-652 had potent inhibitory activity against HIV-1-mediated cell-cell fusion and infection, especially against T-20- and C34-resistant virus. Therefore, our works provide important information for understanding the core structure of the fusion-active gp41 and for designing novel anti-HIV peptides.

Published ahead of print on 16 April 2008.